You are here: Industry Insights > Curadev

News List

Curadev and Bayer agreement shows switch in gears towards STING antagonists: GlobalData expresspharma
April 17, 2020
Globally, there are 42 STING agonists and 8 STING antagonists under development.
Bayer enlists Curadev in STING antagonist collaboration pharmatimes
March 26, 2020
Bayer and Curadev have announced a novel research collaboration and license agreement for Curadev’s Stimulator of Interferon Genes (STING) antagonist program.
Bayer signs drug development and licensing deal with Curadev pharmaceutical-technology
March 25, 2020
German healthcare company Bayer has entered into a research collaboration and licence agreement with India-based drug discovery firm Curadev.
Bayer and Curadev sign research collaboration and license agreement to develop novel STING antagonists across indications expresspharma
March 24, 2020
The collaboration aims to discover new drug candidates for the treatment of lung diseases, cardiovascular diseases and other inflammatory diseases.
Curadev, Endo Pharma oncology program reaches milestone biospectrumasia
October 29, 2018
Curadev, Endo Pharma oncology program reaches milestone
Curadev in research partnership with UT Southwestern Medical Center expressbpd
December 12, 2017
Curadev Pharma, India and UT Southwestern Medical Center in Dallas, USA have announced a translational research partnership to identify small molecule drugs for the treatment of specific cancers.
Curadev Announces Partnership with University of Texas Southwestern Medical Center americanpharmaceuticalreview
December 08, 2017
Curadev and UT Southwestern Medical Center in Dallas announce a translational research partnership to identify small molecule drugs for the treatment of specific cancers.